Locations:
Search IconSearch
October 3, 2018/Cancer

First Prostate Surgery Performed in U.S. Using Single Port SP Robot

Surgeons completed radical prostatectomy using new-generation robot

SP-Port-Robot-1-650×450

Cleveland Clinic is the first hospital in the country to successfully perform surgeries using the Single Port SP Robot, which inserts all surgical instruments through one small abdominal incision, improving surgical outcomes and allowing quicker patient recovery.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

New generation robot used in 3 surgeries

On Sept. 28, Cleveland Clinic surgeons used the SP Robot to perform three surgeries — two surgeries to remove cancerous prostates and one surgery to remove an enlarged prostate blocking the urinary system through the bladder.

Jihad Kaouk, MD, Director of the Center for Robotic and Image Guided Surgery in the Glickman Urologic and Kidney Institute, was the first to perform and publish on robotic single-port surgery in 2008 using standard robotic systems and coining the phrase R-LESS (robotic laparoendoscopic single site surgery).

After completing and publishing the first ever clinical use for the SP robot in Europe, Dr. Kaouk and his team also performed last week’s radical prostatectomies and transvesical simple prostatectomy at Cleveland Clinic. The new purpose-built robotic SP system will allow the single port approach to be more feasible.

Making the previously impossible possible

“We anticipate that this new generation of robots will allow for new and different routes of surgeries that haven’t previously been possible,” Dr. Kaouk says. “For example, we can now go through a patient’s perineum instead of their belly to perform prostate surgery and avoid touching the bowel, or work through the retroperitoneal space to perform kidney surgery without entering the abdomen, allowing for quicker recovery time.”

Currently, the SP Robot is only FDA-approved for urologic surgeries, with plans to expand to ENT and colorectal surgeries in the near future.

“We are proud to offer this surgical approach and be on the forefront of surgical innovation,” adds Mark A. Taylor, MD, Chairman of Surgical Operations at Cleveland Clinic.

Advertisement

Dr. Kaouk worked with the Intuitive Inc. team of engineers to test and improve the new robotic system. Dr. Kaouk is a paid consultant, speaker or member of the advisory committee for Endocare, Inc. and Intuitive Surgical, Inc.

Advertisement

Related Articles

Surgeon
June 30, 2025/Cancer/News & Insight
Potential for Deintensification of Surgical Interventions in Low-Risk Breast Cancer

Reconsidering axillary lymph node dissection as well as depth of surgical margins

Dendritic cell
June 26, 2025/Cancer/News & Insight
Avelumab Induces Natural Killer Cell Activation and Dendritic Cell Crosstalk

Researchers uncover profound differences in the mechanism of action between different PD-L1 checkpoint inhibitors

World map
June 19, 2025/Cancer/News & Insight
Breaking Barriers to Cancer Care: Cleveland Clinic’s Global Approach

A multi-pronged strategy for tackling cancer access problems

CAR T-cell therapy illustration
June 12, 2025/Cancer/News & Insight
First-Ever U.S. Trial of CAR T-Cell Therapy for Relapsed/Refractory AL Amyloidosis

Early results show patients experiencing deep and complete response

Genomic profiling
June 10, 2025/Cancer
Cleveland Clinic’s Hemato-Oncology Team Spearheads the Development of Guidelines for Genomic Profiling of MDS to Inform Allo-HCT

Inclusion of genomic profiling and risk factors recommended for treatment planning

scan showing cholangiocarcinoma
June 5, 2025/Cancer/News & Insight
Exploring Novel Therapeutic Avenues in Advanced Cholangiocarcinoma: Lessons from the EA2187 Trial

Collaborative research effort underscores the urgent need for effective second-line therapies in this rare, aggressive cancer

Anticoagulant sign
June 4, 2025/Cancer/News & Insight
Direct-Acting Oral Anticoagulants Safe for Patients with Brain Metastasis

Largest study to date comparing direct-acting oral anticoagulants to low-molecular-weight heparin

Ad